TI
VERV

Trexquant Investment’s Verve Therapeutics VERV Stock Holding History

Trexquant Investment’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-229,781
Closed -$2.58M – 1938
2025
Q2 		$2.58M Sell
229,781
-358,636
-61% -$2.04M 0.03% 800
2025
Q1 		$2.69M Sell
588,417
-47,430
-7% -$318K 0.03% 755
2024
Q4 		$3.59M Buy
635,847
+80,345
+14% +$453K 0.04% 645
2024
Q3 		$2.69M Buy
555,502
+32,109
+6% +$186K 0.03% 698
2024
Q2 		$2.55M Buy
523,393
+360,630
+222% +$2.27M 0.04% 646
2024
Q1 		$2.16M Buy
+162,763
New +$2.16M 0.04% 621
2022
Q4 		– Sell
-21,121
Closed -$726K – 1758
2022
Q3 		$726K Buy
+21,121
New +$674K 0.03% 651

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Trexquant Investment's VERV Position: Q3 2025 in Review

Trexquant Investment sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 229,781 shares — an estimated $2.58M sold.

Trexquant Investment first reported a position in VERV in Q3 2022 and held it in 7 quarters. The position peaked at $3.59M in Q4 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Trexquant Investment reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Trexquant Investment sold 229,781 Verve Therapeutics shares in Q3 2025, an estimated $2.58M.
  • Trexquant Investment first reported a position in Verve Therapeutics in Q3 2022 and held it in 7 quarters.
  • Trexquant Investment's Verve Therapeutics position peaked at $3.59M in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Trexquant Investment's 13F filing for Q3 2025, filed 14 Nov 2025.